about
Tissue Regeneration: A Silk RoadDrug discovery in ophthalmology: past success, present challenges, and future opportunitiesLipid Nanoparticles for Ocular Gene DeliverySodium dependent multivitamin transporter (SMVT): a potential target for drug deliveryNonionic surfactant vesicles in ocular delivery: innovative approaches and perspectivesAn overview of clinical and commercial impact of drug delivery systemsNovel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth HormoneLiposomes and nanotechnology in drug development: focus on ocular targetsBimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluationGene Delivery by Subconjunctival Injection of Adenovirus in Rats: A Study of Local Distribution, Transgene Duration and SafetysFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In VivoUtilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularizationFit for the Eye: Aptamers in Ocular DisordersTopical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal NeovascularizationGene therapy for ocular diseases meditated by ultrasound and microbubbles (Review)Ultrasound-enhanced ocular delivery of dexamethasone sodium phosphate: an in vivo study.Ultrasound-enhanced delivery of antibiotics and anti-inflammatory drugs into the eye.Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degenerationSynthesis and evaluation of a nanoglobular dendrimer 5-aminosalicylic Acid conjugate with a hydrolyzable schiff base spacer for treating retinal degeneration.TGF-β2-mediated ocular hypertension is attenuated in SPARC-null mice.Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivoOcular delivery of macromoleculesSingle compartment drug delivery.Targeted disruption of core 1 β1,3-galactosyltransferase (C1galt1) induces apical endocytic trafficking in human corneal keratinocytes.Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitisTherapeutic applications of ultrasound in ophthalmology.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.Multifunctional PEG retinylamine conjugate provides prolonged protection against retinal degeneration in mice.Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis.Ocular pharmacokinetics of naringenin eye drops following topical administration to rabbitsPhysicochemical characterization and toxicological evaluation of plant-based anionic polymers and their nanoparticulated system for ocular delivery.Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure.Recent patents on ophthalmic nanoformulations and therapeutic implicationsExpansion of first-in-class drug candidates that sequester toxic all-trans-retinal and prevent light-induced retinal degeneration.Evaluation of topical hesperetin matrix film for back-of-the-eye deliveryTopical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation.Multivalent hyaluronic acid bioconjugates improve sFlt-1 activity in vitro.Positively charged micelles based on a triblock copolymer demonstrate enhanced corneal penetration.
P2860
Q26741383-C21D2B3D-66C3-4359-955A-03A83AAA1296Q26771638-68FBF4D5-7F18-4073-A7ED-F1E44815CB2EQ26823895-E3B84D70-B0E8-490D-A8AD-E28B88BC943FQ26863420-D12974C4-9B71-4CE3-9349-C619F059B7AFQ26999057-A76BDD75-C0E1-4B1F-B78C-3D77F3271F14Q27007143-F31F7054-B292-4BC6-A1E9-8D9E81CC1E4DQ27021208-78DEA22C-9179-41CE-B05C-79B9090E9DECQ27687657-43FDC5CA-603E-4AFE-B672-D4EF83AE246AQ28538289-C17C8DEA-14F0-458F-9065-781F39229A5BQ28551360-2F673755-5C1D-4256-9BFE-6D1C39171F5FQ28552652-E1860DCD-7A2F-4B5B-B381-52F779A660F3Q28740612-771171A9-5546-47E2-A45A-A75247B0E121Q28828283-6CDE94A8-1C83-43C8-BEB7-25AA2AA689D7Q28831101-A88B5C5F-8AC3-4E44-ABE9-BA4BC16C7186Q30397703-09C8F961-4EA5-42F2-A37F-554639500AEEQ30436895-5198CC5E-DCEE-4FEA-A687-360B5584BC27Q30441010-1A6C4F54-EF98-40D4-B66C-D6E8CA4BCEC2Q30565636-4EB5BD95-A76C-4B16-A8BD-99B8796E724DQ33768680-28F8684E-89EB-45EE-B9C8-5818414C3BC8Q33835663-2AAE20B4-D52C-4AAF-9D63-BA9E72B8F97BQ34062422-B13EA59F-8C6B-4F66-839D-D92E2117C7F9Q34079676-3101B866-647E-4D35-AC53-B56FBA979B30Q34263907-6DB2D089-35EB-4137-97CB-ACEF9E775EA8Q34264840-4F410D16-C1E9-47D9-8780-17ECBF90EF2CQ34265155-789D2E01-41A3-4611-A805-8F95E6A81CF0Q34279199-3209DAE2-28FD-43A5-9C17-2B8193FA7885Q34530196-6B628F3C-FBE4-42FD-A4E9-15F6E345D332Q34627019-613069A2-2048-482A-BBEC-296B17276948Q34669685-3B87749C-E667-45BD-A62A-CC79FD37F274Q34718470-A7D1CFEE-DE1B-49FF-90B8-3E4CAEEAA8F8Q34862764-E6908570-804E-4448-B13C-92B0B95F69F8Q34952945-F582B7AD-1957-4A1E-A839-88F0546AC239Q34953629-76D4392A-4309-402B-8C14-83C37CB0A0A0Q35043004-D1DAEB05-14A7-4255-9A68-45F488F5F5B4Q35156386-A7618615-0FC9-47CC-9F3F-4CBF5FA830F2Q35602734-0718EDE5-0636-41DA-BE73-C83A2FDD7693Q35759073-144D6649-5279-4F6D-8E82-967AD259D6D3Q35892589-C75985EA-C736-47EC-80D1-16AD2C79BA26Q35991894-4F3B3D98-8C88-4290-9BC9-744272E3B9D7Q36116578-21BD1353-6090-4169-836F-1F720691591F
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ocular drug delivery.
@ast
Ocular drug delivery.
@en
type
label
Ocular drug delivery.
@ast
Ocular drug delivery.
@en
prefLabel
Ocular drug delivery.
@ast
Ocular drug delivery.
@en
P2093
P2860
P1433
P1476
Ocular drug delivery.
@en
P2093
Ashim K Mitra
Ashwin Parenky
Hari Krishna Ananthula
Ripal Gaudana
P2860
P2888
P304
P356
10.1208/S12248-010-9183-3
P407
P577
2010-05-01T00:00:00Z
P5875
P6179
1025688772